PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. Jul 24, 2012; 79(4): 342–347.
PMCID: PMC3400092
A candidate gene for autoimmune myasthenia gravis
Guida Landouré, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIH, visiting fellowship (2004-2007, 2009-2011)
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Melanie A. Knight, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Horia Stanescu, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Addis A. Taye, BS, Yijun Shi, BS,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Oumarou Diallo, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Janel O. Johnson, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Dena Hernandez, MSc,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • Government employee NIH Biologist
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Bryan J. Traynor, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • The Italian Football Federation, travel expenses; American Academy of Neurology, travel expenses; Cold Spring Harbor Laboratories, travel expenses; ARISLA, travel expenses.
Editorial Boards:
  • Neurology, editorial board, 2011
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • National Institutes of Health
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • The Myasthenia Gravis Foundation; the ALS Association; The Packard Center for ALS Research; FIGC (The Italian Football Federation)
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Leslie G. Biesecker, MD,
Scientific Advisory Boards:
  • Uncompensated advisor to the Illumina Corporation.; Member, board of directors, American Society Human Genetics
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • American Journal of Medical Genetics, Ed Board/Deputy/Assoc. Editor, 2000-present; Clinical Dysmorphology, Ed Board 1999-present; BMC Medicine, Ed Board, 2009-present
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • National Human Genome Research Institute, NIH
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Intramural research support from the NHGRI, NIH.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Proteus syndrome foundation, USA & UK. Gift to support sequencing research.
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Abdel Elkahloun, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • This work is part of my duties at the NIH US government.
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • This work is part of my duties at the NIH US government.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Carlo Rinaldi, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Angela Vincent, MD, MSc, FRCPath, FRS,
Scientific Advisory Boards:
  • Patrick Berthoud Trust Chair 2000-2009. MGFA SAB Member 2005-2009
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Travel and speaker honorarium, Baxter, 2009
Editorial Boards:
  • Associate Editor Brain
Patents:
  • MuSK antibodies 2001 US Patent #7267820 (Issued 9/11/07) CASPR2, Lgi1, Contactin2 antibodies 2008 JA46294P.GBA
Publishing Royalties:
  • Clinical Neuroimmunology Blackwells 2005 Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press 2010
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Athena Diagnostics
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • The neuroimmunology service that I direct brings in income to my department
Research Support, Commercial Entities:
  • Euroimmun AG, 2010/2011; NIHR Oxford Biomedical Research Centre, 2007-present
Research Support, Government Entities:
  • EU network grant
Research Support, Academic Entities:
  • NIHR Biomedical Research Centre Oxford
Research Support, Foundations and Societies:
  • Sir Halley Stewart Trust
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • Musk antibody royalties from Athena Diagnostics Musk antibody royalties from RSR Ltd, Cardiff, UK paid to university Possible future LGI1/CASPR2/Contactin-2 royalties from Euroimmun AG Non-financial disclosures: Association with Myasthenia Gravis Foundation of America
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Nick Willcox, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Robert Kleta, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Nephron Physiology, Editor, 2008-2013
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Kenneth H. Fischbeck, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Travel funds provided for service on advisory boards for the following organizations: Hereditary Disease Foundation, Kennedy’s Disease Association, Spinal Muscular Atrophy Foundation, Biogen Idec, Inc., TREAT-NMD Neuromuscular Network, Muscular Dystrophy Association, Prosensa, Association Francaise contre les Myopathies
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NIH/NINDS only
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIH/NINDS intramural research funds
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
and Barrington G. Burnett, PhDcorresponding author
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • National Institutes of Health, Research Fellow
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • National Institutes of Health, NINDS intramural funds
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
From the Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (G.L., M.A.K., A.A.T., Y.S., O.D., C.R., K.H.F., B.G.B.), National Human Genome Research Institute (H.S., L.G.B., A.E., R.K.), Laboratory of Neurogenetics, National Institute of Aging (J.O.J., D.H., B.J.T.), and Genetic Disease Research Branch and NIH Intramural Sequencing Center (L.G.B.), National Institutes of Health, Bethesda, MD; Department of Medicine (G.L., H.S., R.K.), University College London, London, UK; Service de Neurologie (G.L.), Centre Hospitalo-Universitaire du Point “G,” Université de Bamako, Mali; and Department of Clinical Neurology (A.V., N.W.), University of Oxford, Oxford, UK.
For the NIH Intramural Sequencing Center
corresponding authorCorresponding author.
Deceased.
Correspondence & reprint requests to Dr. Burnett: burnettb/at/ninds.nih.gov
Study funding: Supported by intramural funds from the National Institute of Neurological Disorders and Stroke at the NIH and the National Human Genome Research Institute.
Received September 16, 2011; Accepted December 14, 2011.
Objective:
We sought to identify a causative mutation in a previously reported kindred with parental consanguinity and 5 of 10 siblings with adult-onset autoimmune myasthenia gravis.
Methods:
We performed genome-wide homozygosity mapping, and sequenced all known genes in the one region of extended homozygosity. Quantitative and allele-specific reverse transcriptase PCR (RT-PCR) were performed on a candidate gene to determine the RNA expression level in affected siblings and controls and the relative abundance of the wild-type and mutant alleles in a heterozygote.
Results:
A region of shared homozygosity at chromosome 13q13.3–13q14.11 was found in 4 affected siblings and 1 unaffected sibling. A homozygous single nucleotide variant was found in the 3′-untranslated region of the ecto-NADH oxidase 1 gene (ENOX1). No other variants likely to be pathogenic were found in genes in this region or elsewhere. The ENOX1 sequence variant was not found in 764 controls. Quantitative RT-PCR showed that expression of ENOX1 decreased to about 20% of normal levels in lymphoblastoid cells from individuals homozygous for the variant and to about 50% in 2 unaffected heterozygotes. Allele-specific RT-PCR showed a 55%–60% reduction in the level of the variant transcript in heterozygous cells due to reduced mRNA stability.
Conclusion:
These results indicate that this sequence variant in ENOX1 may contribute to the familial autoimmune myasthenia in these patients.
Myasthenia gravis (MG) is usually sporadic, but about 4% of patients have a positive family history.1 In addition to the congenital myasthenic syndromes caused by inherited defects in the acetylcholine receptor (AChR) and other constituents of the neuromuscular junction,24 familial clustering has been reported with autoimmune MG.1,57 A role for genetic factors in autoimmune MG has been suggested6,810 including polymorphisms that may influence the production of anti-AChR antibodies.1113 However, no single gene defect has yet been implicated in familial autoimmune MG.
We previously reported an Italian American family with parental consanguinity where 5 out of 10 siblings had late-onset autoimmune MG.10 No HLA haplotype was shared by all the affected family members, nor did polymorphisms in the AChR β subunit or the α and β subunits of the T-cell receptor cosegregate with the myasthenia.10 We sought to identify and characterize other candidate genes in this family and found a sequence variant in one gene, ENOX1, strongly linked to the disease in this family.
Standard protocol approvals, registrations, and patient consents.
The collection of control samples was approved by the ethics committees of the contributing centers. Informed and written consent was obtained from all study participants.
Patients.
Seven family members (4 affected, 2 unaffected, and 1 with uncertain diagnosis) were previously interviewed and examined by neurologists.10 For the current study, B lymphoblastoid cell lines (unaffected siblings GM12023, GM12027; affected siblings GM11858, GM11947, GM12129, GM12355; unknown disease status GM12492; and unrelated controls GM12679, GM12560, GM12664, GM12671, GM12691) were obtained from the Coriell Institute (Coriell Institute for Medical Research, Camden, NJ).
Genetic analysis.
Genomic DNA from the 7 siblings (4 affected, 2 unaffected, and 1 with unknown status) was used for a genome-wide scan with 2,000 microsatellite markers (DeCODE) and in SNP array analysis (Illumina Infinium II HumanHap550 SNP chips, Illumina, San Diego, CA).
Homozygosity mapping and multipoint analysis were performed, and a lod score was determined.14,15 Haplotype reconstruction was done with the Genehunter software 2.0.16 Coding regions and splice sites of all genes in the linked region were sequenced.
For exome sequencing, DNA from 4 affected individuals was enriched using SureSelect Exome target enrichment technology (version 1.0, Agilent, Santa Clara, CA) and sequenced on a Genome Analyzer IIx (Illumina). Sequence alignment and variant calling were performed against the reference human genome (UCSC hg 18) using the Genome Analysis Toolkit (Broad Institute, Cambridge, MA). The ClinSeq™ exomes were analyzed as previously described.17,18
Sequence variants were filtered against the dbSNP database (build 135), confirmed by Sanger sequencing, and tested in at least 200 ethnically matched controls, and in the ClinSeq™ cohort.19
RNA analysis.
Specific primers and probes to amplify the internal control (human β-glucuronidase or 18S) and the ENOX1 gene were purchased from Applied Biosystems (Foster City, CA). Quantitative reverse transcriptase PCR (qRT-PCR) reactions were performed for gene expression analysis using an ABI protocol (Applied Biosystems). We compared samples from all 7 available family members and 5 unrelated controls.
We performed allele-specific RT-PCR using RNA extracted from lymphoblastoid cells of the 2 heterozygotes (ABI TaqMan Allelic Discrimination genotyping platform, Applied Biosystems; primers and probes outlined in table e-1 on the Neurology® Web site at www.neurology.org) cultured in the presence or absence of 5 μg/mL actinomycin D for up to 8 hours to inhibit transcription. The ratio of mutant to wild-type transcripts was determined by allele-specific RT-PCR.
Clinical findings.
As reported previously,10 ages at MG onset ranged from 50 to 71 years (figure 1). Symptoms included ptosis, diplopia, and weakness in the neck and extremities, and neurologic examination showed fatigability of upward and lateral gaze. Three patients had elevated anti-AChR antibody titers. A fourth patient had normal anti-AChR antibody titer, but complained of drooping eyelids and double vision with diurnal variation. His neurologic examination showed marked fatigability and horizontal diplopia on lateral gaze. Other autoimmune diseases including insulin-dependent diabetes mellitus and thyroid disease were present in family members with and without MG.
Figure 1
Figure 1
Region of shared homozygosity on chromosome 13 found by linkage analysis using microsatellite markers and single nucleotide polymorphism arrays
Genetic analysis.
We found evidence for linkage in a region of shared homozygosity on chromosome 13q13.3–13q14.11 with a lod score of 3.18 in the affected individuals; it was confirmed by haplotype reconstruction showing homozygosity in all affected siblings and 1 unaffected sibling (figure 1); genotyping failed for 1 unaffected sibling. The region of homozygosity included 7.4 Mb of genomic DNA, and contained 37 known protein-encoding genes. Another locus of shared compound heterozygous haplotypes in the affected siblings was found using multipoint analysis at chromosome 2q36.3–2q37.1 with a lod score of 2.18 (figure e-1A).
High-resolution SNP genotyping of samples from the 4 available affected individuals confirmed the region of homozygosity on chromosome 13 (figure e-1B). Sequencing of the coding region of all 37 genes in the homozygous region on chromosome 13 identified 2 homozygous single nucleotide variants. One is located in the 3′ UTR of ENOX1 (c.*35A>G). This change was present in all 4 available affected siblings and in the unaffected homozygous sister (II-1, figure 1). This variant was not found in 215 ethnically matched controls and in 559 exomes sequenced in the ClinSeq™ cohort.19
We subsequently sequenced ENOX1 in 83 UK patients with sporadic autoimmune MG, but none had the c.*35A>G sequence variant. We thus do not have evidence to implicate mutations in ENOX1 in sporadic myasthenia. This variant was also not found in 6 Italian patients with familial autoimmune MG. In addition to this change in ENOX1, a homozygous variant was identified in the coding region of the periostin gene (POSTN) (c.1944C>A). This variant was not seen in 196 European and American controls, but is predicted to be synonymous (I648I).
We did not find sequence variants in the coding regions of any other gene in the region of homozygosity on chromosome 13, or in the genes for AChR subunits δ and γ, located on chromosome 2.
Whole exome sequencing identified a heterozygous sequence variant (c.649G>T, p.Ala217Ser) in all 4 affected individuals in the SPHK1-interactor, AKAP domain-containing gene (SPHKAP) located in the chromosome 2q36.3 region. Sequencing of its coding region in all available siblings identified another heterozygous sequence variant (c.4771G>A, p.Glu1591Lys), which cosegregated with the phenotype. However, these variants were either seen in controls and ClinSeq™ subjects or listed in dbSNP database. Screening of 38 patients with late-onset autoimmune MG showed 2 heterozygous sequence variants in SPHKAP (p.Val90Met and p.Glu1329Lys) that were also seen in ClinSeq™ samples.
Reporter assays of ENOX1 3′ UTR activity.
Use of miRBase microRNA prediction software (http://www.mirbase.org/search.shtml) indicated that the 3′ UTR variant we identified in ENOX1 might destroy 2 existing microRNA-binding sites, hsa-miR-432 and hsa-miR-324-3p, and create a new one, hsa-miR-518c*. However, we did not detect changes in the activity of a wild-type ENOX1 3′ UTR luciferase reporter in the presence of exogenous hsa-miR-324-3p or hsa-mir-432. Nor did exogenous hsa-mir-518c* affect the activity of the patient-derived mutant 3′ UTR ENOX1 luciferase reporter (figure e-2).
RNA analysis.
Quantitative RT-PCR showed that the expression of ENOX1 was lower in the homozygous siblings than in either the heterozygous sister or unrelated controls in a gene dose-dependent manner. The homozygotes had approximately 20% and the unaffected heterozygotes 50% of the control level (figure 2). Allele-specific RT-PCR showed a 55%–60% lower level of the mutant transcript than the wild-type in heterozygous cells (table 1). Moreover, mRNA stability assays showed faster degradation of the mutant transcripts, as reflected by decreasing mutant/wild-type ratios with time after addition of actinomycin D to inhibit transcription (table 2).
Figure 2
Figure 2
Quantitative reverse transcriptase PCR assays of the ENOX1 transcript levels (y-axis) in the family members and unrelated controls
Table 1
Table 1
Relative transcript levels of ENOX1 transcripts
Table 2
Table 2
Relative allele ratios of ENOX1 transcripts after incubation with actinomycin Da
By contrast, we found no patient/control difference in POSTN transcript levels by RT-PCR, and no evidence of a splicing defect by cDNA sequencing (data not shown). In addition, Western blot analysis with an anti-periostin antibody showed no difference between affected and unaffected siblings (figure e-3).
Familial clustering of autoimmune MG has been reported previously. Although no causative mutation has yet been identified, this seems likely in the present family because of the parental consanguinity and the late onset of MG in 5 siblings who had lived apart for up to 50 years. Sequencing of all known genes across the linked region of chromosome 13 showed homozygous single nucleotide variants in 2 genes (ENOX1 and POSTN). Based on RNA and protein analysis, the variation in the POSTN gene is unlikely to be causative in this family. One asymptomatic sibling (II-1; figure 1) was also homozygous for the haplotype shared by the affected individuals at the chromosome 13 locus, possibly because of incomplete penetrance.
Ecto-NADH oxidase (ENOX) proteins are growth-related cell surface enzymes that catalyze hydroquinone oxidation and protein disulfide-thiol interchange. The 2 enzymatic activities oscillate with a periodicity of 24 minutes for constitutively expressed ENOX1, unlike any other oxidases or protein disulfide isomerases.20 In principle, the ENOX1 mutation might predispose to MG by affecting the autoimmune response or the motor endplate (or both). ENOX1 is highly expressed in fetal brain and at lower levels in skeletal muscle, thymus, and lymph nodes. It plays a role in plasma membrane transport pathways reducing nicotinamide adenine dinucleotide (NAD+) to NADH. NAD and its metabolites are involved in energy metabolism, signal transduction, aging, and cellular injury. They also are involved in immune regulation by inhibiting T-lymphocyte proliferation24 and control of signaling via CD38.2123 Studies have implicated NAD+ and NADH in the induction of cell death in CD4+ and CD25+ cells,24 which, in cooperation with natural killer T cells, may play a role in the prevention of autoimmune MG.25 Other studies have shown that NAD+ and NADH are involved in the regulation of gene expression.26
The 3′ UTRs of mRNAs play important roles in post-transcriptional regulation of gene expression, by modulating mRNA localization, stability, and translation, in part through association with microRNAs.27 The sequence variant identified here in ENOX1 was predicted to destroy 2 existing microRNA-binding sites and to create a new one. However, we did not detect changes in reporter activity of the wild-type or mutant ENOX1 3′ UTR luciferase reporter in the presence of these specific microRNAs. Nevertheless, it remains possible that this variant affects the binding of other microRNAs that are not predicted by current algorithms. Alternatively, the variant may affect the secondary structure of the transcript, altering its stability.
Based on the homozygosity mapping and sequence data, and also on its reduced expression and what is known of its function, ENOX1 is a candidate gene for the autoimmune MG in the family described here. Although other factors cannot be fully excluded, this finding may provide novel insights into the etiology of MG and other autoimmune diseases.
Supplementary Material
Data Supplement
Accompanying Editorial
ACKNOWLEDGMENT
M.A.K. and B.G.B. were supported by NINDS Competitive Postdoctoral Fellowships. The authors thank Anna Paola Batocchi, of the Università Cattolica del Sacro Cuore, Rome, for providing DNA from familial autoimmune myasthenia patients. The authors thank Jim Nagle and Deborah Kauffmann at the NINDS DNA sequencing facility for help with sequencing, Animesh Tandon for advice regarding the microRNA analysis, Ami Mankodi for advice on RNA analysis studies, Jennifer Puck and Richard Siegel for advice and input, and our clinical colleagues for access to the patients with sporadic MG.
GLOSSARY
AChRacetylcholine receptor
MGmyasthenia gravis
NADnicotinamide adenine dinucleotide
qRT-PCRquantitative reverse transcriptase PCR
RT-PCRreverse transcriptase PCR

Footnotes
Editorial, page 304
Supplemental data at www.neurology.org
AUTHOR CONTRIBUTIONS
Guida Landouré, MD, PhD: contributed to linkage analysis, completed sequencing, mutagenesis RNA and miRNA analysis, and drafted the manuscript. Melanie A. Knight, PhD: designed experiments and performed sequencing and RNA analysis. Horia Stanescu, MD, PhD: performed the linkage analysis. Addis A. Taye, BS: performed sequencing and Western blotting. Yijun Shi, BS: performed sequencing and cloning. Oumarou Diallo, MD: sequenced controls and sporadic autoimmune myasthenia patients. Janel O. Johnson, PhD: performed exome sequencing. Dena Hernandez, MSc: performed homozygosity SNP analysis. Bryan J. Traynor, MD: performed exome sequencing. Leslie G. Biesecker, MD: performed ClinSeq exome analysis. Abdel Elkahloun, PhD: performed expression analysis. Carlo Rinaldi, MD: performed sequencing of Italian familial autoimmune myasthenia patients. Angela Vincent, MD, MSc, FRCPath: provided autoimmune myasthenia gravis patient samples. Nick Willcox, MD, PhD: provided autoimmune myasthenia gravis patient samples. Robert Kleta, MD, PhD: performed the linkage analysis. Kenneth H. Fischbeck, MD: co-directed the study and co-wrote manuscript. Barrington G. Burnett, PhD: co-directed the study, designed experiments, performed gene expression analysis, RNA and miRNA analysis, and completed the manuscript. Statistical analysis performed by Barrington G. Burnett.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.
1. Szobor A. Myasthenia gravis: familial occurrence: a study of 1100 myasthenia gravis patients. Acta Med Hung 1989;46:13–21. [PubMed]
2. Engel AG, Ohno K, Milone M, et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1996;5:1217–1227. [PubMed]
3. Chevessier F, Faraut B, Ravel-Chapuis A, et al. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 2004;13:3229–3240. [PubMed]
4. Muller JS, Baumeister SK, Rasic VM, et al. Impaired receptor clustering in congenital myasthenic syndrome with novel RAPSN mutations. Neurology 2006;67:1159–1164. [PubMed]
5. Evoli A, Batocchi AP, Zelano G, et al. Familial autoimmune myasthenia gravis: report of four families. J Neurol Neurosurg Psychiatry 1995;58:729–731. [PMC free article] [PubMed]
6. Marrie RA, Sahlas DJ, Bray GM. Familial autoimmune myasthenia gravis: four patients involving three generations. Can J Neurol Sci 2000;27:307–310. [PubMed]
7. Tan JH, Ho KH. Familial autoimmune myasthenia gravis. Singapore Med J 2001;42:178–179. [PubMed]
8. Oppenheim H. In: Karger S, editor. ed. Lehrbuch der Nervenkrankheiten fur Aerzte und Studierende, 2nd ed. 1898;716.
9. Bu B, Yang M, Xu J, et al. The clinical study and HLA genotyping of 112 familial myasthenia gravis patients. J Tongji Med Univ 1999;19:46–49. [PubMed]
10. Bergoffen J, Zmijewski CM, Fischbeck KH. Familial autoimmune myasthenia gravis. Neurology 1994;44:551–554. [PubMed]
11. Giraud M, Eymard B, Tranchant C, et al. Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis. Genes Immun 2004;5:80–83. [PubMed]
12. Viken MK, Sollid HD, Joner G, et al. Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. Hum Immunol 2007;68:748–755. [PubMed]
13. Lefvert AK, Zhao Y, Ramanujam R, et al. PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol 2008;197:110–113. [PubMed]
14. Kruglyak L, Daly MJ, Lander ES. Rapid multipoint linkage analysis of recessive traits in nuclear families, including homozygosity mapping. Am J Hum Genet 1995;56:519–527. [PubMed]
15. Sobel E, Sengul H, Weeks DE. Multipoint estimation of identity-by-descent probabilities at arbitrary positions among marker loci on general pedigrees. Hum Hered 2001;52:121–131. [PubMed]
16. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347–1363. [PubMed]
17. Teer JK, Bonnycastle LL, Chines PS, et al. Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. Genome Res 2010;20:1420–1431. [PubMed]
18. Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011;365:611–619. [PMC free article] [PubMed]
19. Biesecker LG, Mullikin JC, Facio FM, et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res 2009;19:1665–1674. [PubMed]
20. Chueh PJ, Kim C, Cho N, et al. Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry 2002;41:3732–3741. [PubMed]
21. Bortell R, Moss J, McKenna RC, et al. Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. J Immunol 2001;167:2049–2059. [PubMed]
22. Aksoy P, White TA, Thompson M, Chini EN. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun 2006;345:1386–1392. [PubMed]
23. Chen J, Chen YG, Reifsnyder PC, et al. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol 2006;176:4590–4599. [PubMed]
24. Aswad F, Kawamura H, Dennert G. High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol 2005;175:3075–3083. [PubMed]
25. Liu R, La Cava A, Bai XF, et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005;175:7898–7904. [PubMed]
26. Zheng S, Byrd AS, Fischer BM, et al. Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1. Free Radic Biol Med 2007;42:1398–1408. [PMC free article] [PubMed]
27. Lai EC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002;30:363–364. [PubMed]
Articles from Neurology are provided here courtesy of
American Academy of Neurology